Bulletin
Investor Alert

Market Pulse Archives

Oct. 30, 2019, 7:40 a.m. EDT

Biogen's and Alkermes' Vumerity gets FDA approval for MS; Biogen's stock surges

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Biogen Inc. (BIIB)
  • X
    Alkermes PLC (ALKS)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Tomi Kilgore

Biogen Inc. /zigman2/quotes/201531540/composite BIIB -0.57% and Alkermes PLC /zigman2/quotes/205084517/composite ALKS -1.44% said Wednesday that U.S. Food and Drug Administration approved Vumerity for the treatment of relapsing forms of multiple sclerosis. Biogen's stock surged 2.2% in premarket trading, while Alkermes' stock was still inactive. Biogen holds the exclusive license to commercialize Vumerity worldwide, and plans to make it available in the U.S. in the near futures. Under terms of the licensing agreement with Alkermes, Biogen will pay Alkermes $150 million in connection with the FDA approval. Biogen shares have lost 1.1% year to date through Tuesday and Alkermes' stock has tumbled 32.2%, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.23% has advanced 21.1%.

/zigman2/quotes/201531540/composite
US : U.S.: Nasdaq
$ 216.34
-1.24 -0.57%
Volume: 514,481
Aug. 18, 2022 4:00p
P/E Ratio
15.45
Dividend Yield
N/A
Market Cap
$31.57 billion
Rev. per Employee
$1.04M
loading...
/zigman2/quotes/205084517/composite
US : U.S.: Nasdaq
$ 25.24
-0.37 -1.44%
Volume: 1.35M
Aug. 18, 2022 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$4.21 billion
Rev. per Employee
$530,696
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,283.74
+9.70 +0.23%
Volume: 2.22B
Aug. 18, 2022 5:48p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.